Dr. R. Vermeij | Gynaecoloog, chef de clinique

Studie & opleiding

• 2001-2008: Geneeskunde Rijksuniversiteit Groningen
• 2008-2011: Promotie, proefschrift: “Immunotherapy of Ovarian Cancer”, Universitair Medisch Centrum Groningen, promooren: prof. dr. H.W. Nijman en prof. dr. C.A.H.H. Daemen
• 2011-2018: Arts in opleiding tot specialist, Obstetrie en Gynaecologie, Universitair Medisch Centrum Groningen

Onderzoek & publicaties

• Lövgren T, Sarhan D, Truxová I, Choudhary B, Maas R, Melief J, Nyström M, Edbäck U, Vermeij R, Scurti G, Nishimura M, Masucci, G, Karlsson-Parra A, Lundqvist A, Adamson L, Kiessling R
  Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-g and multiple toll-like receptor agonists
  Cancer Immunol Immunother. 2017 Oct;66(10):1333-1344. doi:10.1007/s00262-017-2029-4
• van Poelgeest MI, Welters MJ, Vermeij R, Kenter GG, Nijman HW, Melief CJ, van der Burg SH,
  et al.
  Vaccination against oncoproteins of HPV16 for noninvasive vulvar/vaginal lesions: lesion clearance is related to the strength of the T-cell response
  Clinical Cancer Research 2016 May 15;22(10):2342-50. doi: 10.1158/1078-0432.CCR-15-2594
• AM Musters, R Vermeij, DMJ Oom, LN Hofman, MR Buist.
  De in- en uitstroom van gynaecologen; cijfers over de periode 2015-2020
  Nederlands Tijdschrift voor Obstetrie & Gynaecologie vol.128, december 2015, pag. 500-505
• Vermeij R, Leffers N, Melief CJ, Deamen T, Nijman HW.
  Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen (review article)
  Current Pharmaceutical Design 2012;18(25):3804-11
• Leffers N, Vermeij R, Hoogeboom BN, Schulze U, Wolf R, Hamming LE, van der Zee AGJ, Melief CJ, van der Burg SH, Daemen T, Nijman HW.
  Long-term clinical and immunological effects of p53-SLP vaccine in ovarian cancer patients
  International Journal of Cancer 2012 Jan 1;130(1):105-12.doi:10.1002/ ijc.25980
• Vermeij R, Leffers N, Hoogeboom BN, Schulze U, Hamming LE, Wolf R, Reyners AKL, Molmans BHW, Hollema H, Bart J, Drijfhout JW, Oostendorp J, van der Zee AGJ, Melief CJ, van der Burg SH, Daemen T, Nijman HW.
  Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer, a single arm phase II study
  International Journal of Cancer 2011 Dec 3;doi:10.1002/ijc.27388
• Vermeij R, de Bock GH, Leffers N, ten Hoor KA, Schulze U, Hollema H, Daemen T, van der Zee AGJ, Nijman HW.
  Tumor infiltrating cytotoxic T-lymphocytes as independent prognostic factor in epithelial ovarian cancer with Wilms’ tumor protein 1 overexpression
  Journal of Immunotherapy 2011;34(6):516-523
• Vermeij R, Leffers N, van der Burg SH, Melief CJ, Daemen T, Nijman HW.
  Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies (review article)
  Journal of Biomedicine and Biotechnology 2011;2011:702146
• Vermeij R, Daemen T, de Bock GH, de Graeff P, Leffers N, Lambeck A, ten Hoor KA, Hollema H, van der Zee AGJ, Nijman HW.
  Potential target antigens for a universal vaccine in epithelial ovarian cancer
  Clinical and Developmental Immunology 2010;2010:891505

Lidmaatschappen

• Nederlandse Vereniging van Obstetrie en Gynaecologie (NVOG)